CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Chief Development Officer acquired 28,500 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 22,500 shares (grant or award)
- 4 Grant or award Baeuerle Patrick acquired 37,500 shares (grant or award)
- 4 Grant or award Zawel Leigh acquired 32,500 shares (grant or award)
- 4 Grant or award Acting Chief Business Officer acquired 16,500 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 37,500 shares (grant or award)
- 4 Other disposition 10% owner disposed of 1,187,734 shares (other)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Michaelson Jennifer sold 4,000 shares at an average $21.42 ($85,669)
- 4 Open-market sale Chief Financial Officer sold 8,000 shares at $25.00 ($200,000)
- 4 Open-market sale Zawel Leigh sold 19,574 shares at $25.00 ($489,350)
- 4 Open-market sale Zawel Leigh sold 1,079 shares at $25.00 ($26,975)
- 4 Open-market sale Michaelson Jennifer sold 4,000 shares at an average $24.51 ($98,048)
- 4 Open-market sale Zawel Leigh sold 7,468 shares at $25.16 ($187,895)
Page 10 of 13 · 253 filings